Cargando…
Clinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: a randomized double-blind sham-controlled clinical trial
BACKGROUND: This study assessed the safety and efficacy of intrathecal injection of umbilical cord tissue mesenchymal stem cells (UCT-MSC) in individuals with cerebral palsy (CP). The diffusion tensor imaging (DTI) was performed to evaluate the alterations in white-matter integrity. METHODS: Partici...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343813/ https://www.ncbi.nlm.nih.gov/pubmed/34362453 http://dx.doi.org/10.1186/s13287-021-02513-4 |
_version_ | 1783734366126473216 |
---|---|
author | Amanat, Man Majmaa, Anahita Zarrabi, Morteza Nouri, Masoumeh Akbari, Masood Ghahvechi Moaiedi, Ali Reza Ghaemi, Omid Zamani, Fatemeh Najafi, Sharif Badv, Reza Shervin Vosough, Massoud Hamidieh, Amir Ali Salehi, Mona Montazerlotfelahi, Hadi Tavasoli, Ali Reza Heidari, Morteza Mohebi, Hossein Fatemi, Ali Garakani, Amir Ashrafi, Mahmoud Reza |
author_facet | Amanat, Man Majmaa, Anahita Zarrabi, Morteza Nouri, Masoumeh Akbari, Masood Ghahvechi Moaiedi, Ali Reza Ghaemi, Omid Zamani, Fatemeh Najafi, Sharif Badv, Reza Shervin Vosough, Massoud Hamidieh, Amir Ali Salehi, Mona Montazerlotfelahi, Hadi Tavasoli, Ali Reza Heidari, Morteza Mohebi, Hossein Fatemi, Ali Garakani, Amir Ashrafi, Mahmoud Reza |
author_sort | Amanat, Man |
collection | PubMed |
description | BACKGROUND: This study assessed the safety and efficacy of intrathecal injection of umbilical cord tissue mesenchymal stem cells (UCT-MSC) in individuals with cerebral palsy (CP). The diffusion tensor imaging (DTI) was performed to evaluate the alterations in white-matter integrity. METHODS: Participants (4–14 years old) with spastic CP were assigned in 1:1 ratio to receive either UCT-MSC or sham procedure. Single-dose (2 × 10(7)) cells were administered in the experimental group. Small needle pricks to the lower back were performed in the sham-control arm. All individuals were sedated to prevent awareness. The primary endpoints were the mean changes in gross motor function measure (GMFM)-66 from baseline to 12 months after procedures. The mean changes in the modified Ashworth scale (MAS), pediatric evaluation of disability inventory (PEDI), and CP quality of life (CP-QoL) were also assessed. Secondary endpoints were the mean changes in fractional anisotropy (FA) and mean diffusivity (MD) of corticospinal tract (CST) and posterior thalamic radiation (PTR). RESULTS: There were 36 participants in each group. The mean GMFM-66 scores after 12 months of intervention were significantly higher in the UCT-MSC group compared to baseline (10.65; 95%CI 5.39, 15.91) and control (β 8.07; 95%CI 1.62, 14.52; Cohen’s d 0.92). The increase was also seen in total PEDI scores (vs baseline 8.53; 95%CI 4.98, 12.08; vs control: β 6.87; 95%CI 1.52, 12.21; Cohen’s d 0.70). The mean change in MAS scores after 12 months of cell injection reduced compared to baseline (−1.0; 95%CI −1.31, −0.69) and control (β −0.72; 95%CI −1.18, −0.26; Cohen’s d 0.76). Regarding CP-QoL, mean changes in domains including friends and family, participation in activities, and communication were higher than the control group with a large effect size. The DTI analysis in the experimental group showed that mean FA increased (CST 0.032; 95%CI 0.02, 0.03. PTR 0.024; 95%CI 0.020, 0.028) and MD decreased (CST −0.035 × 10(-3); 95%CI −0.04 × 10(-3), −0.02 × 10(-3). PTR −0.045 × 10(-3); 95%CI −0.05 × 10(-3), −0.03 × 10(-3)); compared to baseline. The mean changes were significantly higher than the control group. CONCLUSIONS: The UCT-MSC transplantation was safe and may improve the clinical and imaging outcomes. TRIAL REGISTRATION: The study was registered with ClinicalTrials.gov (NCT03795974). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-021-02513-4. |
format | Online Article Text |
id | pubmed-8343813 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-83438132021-08-09 Clinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: a randomized double-blind sham-controlled clinical trial Amanat, Man Majmaa, Anahita Zarrabi, Morteza Nouri, Masoumeh Akbari, Masood Ghahvechi Moaiedi, Ali Reza Ghaemi, Omid Zamani, Fatemeh Najafi, Sharif Badv, Reza Shervin Vosough, Massoud Hamidieh, Amir Ali Salehi, Mona Montazerlotfelahi, Hadi Tavasoli, Ali Reza Heidari, Morteza Mohebi, Hossein Fatemi, Ali Garakani, Amir Ashrafi, Mahmoud Reza Stem Cell Res Ther Research BACKGROUND: This study assessed the safety and efficacy of intrathecal injection of umbilical cord tissue mesenchymal stem cells (UCT-MSC) in individuals with cerebral palsy (CP). The diffusion tensor imaging (DTI) was performed to evaluate the alterations in white-matter integrity. METHODS: Participants (4–14 years old) with spastic CP were assigned in 1:1 ratio to receive either UCT-MSC or sham procedure. Single-dose (2 × 10(7)) cells were administered in the experimental group. Small needle pricks to the lower back were performed in the sham-control arm. All individuals were sedated to prevent awareness. The primary endpoints were the mean changes in gross motor function measure (GMFM)-66 from baseline to 12 months after procedures. The mean changes in the modified Ashworth scale (MAS), pediatric evaluation of disability inventory (PEDI), and CP quality of life (CP-QoL) were also assessed. Secondary endpoints were the mean changes in fractional anisotropy (FA) and mean diffusivity (MD) of corticospinal tract (CST) and posterior thalamic radiation (PTR). RESULTS: There were 36 participants in each group. The mean GMFM-66 scores after 12 months of intervention were significantly higher in the UCT-MSC group compared to baseline (10.65; 95%CI 5.39, 15.91) and control (β 8.07; 95%CI 1.62, 14.52; Cohen’s d 0.92). The increase was also seen in total PEDI scores (vs baseline 8.53; 95%CI 4.98, 12.08; vs control: β 6.87; 95%CI 1.52, 12.21; Cohen’s d 0.70). The mean change in MAS scores after 12 months of cell injection reduced compared to baseline (−1.0; 95%CI −1.31, −0.69) and control (β −0.72; 95%CI −1.18, −0.26; Cohen’s d 0.76). Regarding CP-QoL, mean changes in domains including friends and family, participation in activities, and communication were higher than the control group with a large effect size. The DTI analysis in the experimental group showed that mean FA increased (CST 0.032; 95%CI 0.02, 0.03. PTR 0.024; 95%CI 0.020, 0.028) and MD decreased (CST −0.035 × 10(-3); 95%CI −0.04 × 10(-3), −0.02 × 10(-3). PTR −0.045 × 10(-3); 95%CI −0.05 × 10(-3), −0.03 × 10(-3)); compared to baseline. The mean changes were significantly higher than the control group. CONCLUSIONS: The UCT-MSC transplantation was safe and may improve the clinical and imaging outcomes. TRIAL REGISTRATION: The study was registered with ClinicalTrials.gov (NCT03795974). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-021-02513-4. BioMed Central 2021-08-06 /pmc/articles/PMC8343813/ /pubmed/34362453 http://dx.doi.org/10.1186/s13287-021-02513-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Amanat, Man Majmaa, Anahita Zarrabi, Morteza Nouri, Masoumeh Akbari, Masood Ghahvechi Moaiedi, Ali Reza Ghaemi, Omid Zamani, Fatemeh Najafi, Sharif Badv, Reza Shervin Vosough, Massoud Hamidieh, Amir Ali Salehi, Mona Montazerlotfelahi, Hadi Tavasoli, Ali Reza Heidari, Morteza Mohebi, Hossein Fatemi, Ali Garakani, Amir Ashrafi, Mahmoud Reza Clinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: a randomized double-blind sham-controlled clinical trial |
title | Clinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: a randomized double-blind sham-controlled clinical trial |
title_full | Clinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: a randomized double-blind sham-controlled clinical trial |
title_fullStr | Clinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: a randomized double-blind sham-controlled clinical trial |
title_full_unstemmed | Clinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: a randomized double-blind sham-controlled clinical trial |
title_short | Clinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: a randomized double-blind sham-controlled clinical trial |
title_sort | clinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: a randomized double-blind sham-controlled clinical trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343813/ https://www.ncbi.nlm.nih.gov/pubmed/34362453 http://dx.doi.org/10.1186/s13287-021-02513-4 |
work_keys_str_mv | AT amanatman clinicalandimagingoutcomesafterintrathecalinjectionofumbilicalcordtissuemesenchymalstemcellsincerebralpalsyarandomizeddoubleblindshamcontrolledclinicaltrial AT majmaaanahita clinicalandimagingoutcomesafterintrathecalinjectionofumbilicalcordtissuemesenchymalstemcellsincerebralpalsyarandomizeddoubleblindshamcontrolledclinicaltrial AT zarrabimorteza clinicalandimagingoutcomesafterintrathecalinjectionofumbilicalcordtissuemesenchymalstemcellsincerebralpalsyarandomizeddoubleblindshamcontrolledclinicaltrial AT nourimasoumeh clinicalandimagingoutcomesafterintrathecalinjectionofumbilicalcordtissuemesenchymalstemcellsincerebralpalsyarandomizeddoubleblindshamcontrolledclinicaltrial AT akbarimasoodghahvechi clinicalandimagingoutcomesafterintrathecalinjectionofumbilicalcordtissuemesenchymalstemcellsincerebralpalsyarandomizeddoubleblindshamcontrolledclinicaltrial AT moaiedialireza clinicalandimagingoutcomesafterintrathecalinjectionofumbilicalcordtissuemesenchymalstemcellsincerebralpalsyarandomizeddoubleblindshamcontrolledclinicaltrial AT ghaemiomid clinicalandimagingoutcomesafterintrathecalinjectionofumbilicalcordtissuemesenchymalstemcellsincerebralpalsyarandomizeddoubleblindshamcontrolledclinicaltrial AT zamanifatemeh clinicalandimagingoutcomesafterintrathecalinjectionofumbilicalcordtissuemesenchymalstemcellsincerebralpalsyarandomizeddoubleblindshamcontrolledclinicaltrial AT najafisharif clinicalandimagingoutcomesafterintrathecalinjectionofumbilicalcordtissuemesenchymalstemcellsincerebralpalsyarandomizeddoubleblindshamcontrolledclinicaltrial AT badvrezashervin clinicalandimagingoutcomesafterintrathecalinjectionofumbilicalcordtissuemesenchymalstemcellsincerebralpalsyarandomizeddoubleblindshamcontrolledclinicaltrial AT vosoughmassoud clinicalandimagingoutcomesafterintrathecalinjectionofumbilicalcordtissuemesenchymalstemcellsincerebralpalsyarandomizeddoubleblindshamcontrolledclinicaltrial AT hamidiehamirali clinicalandimagingoutcomesafterintrathecalinjectionofumbilicalcordtissuemesenchymalstemcellsincerebralpalsyarandomizeddoubleblindshamcontrolledclinicaltrial AT salehimona clinicalandimagingoutcomesafterintrathecalinjectionofumbilicalcordtissuemesenchymalstemcellsincerebralpalsyarandomizeddoubleblindshamcontrolledclinicaltrial AT montazerlotfelahihadi clinicalandimagingoutcomesafterintrathecalinjectionofumbilicalcordtissuemesenchymalstemcellsincerebralpalsyarandomizeddoubleblindshamcontrolledclinicaltrial AT tavasolialireza clinicalandimagingoutcomesafterintrathecalinjectionofumbilicalcordtissuemesenchymalstemcellsincerebralpalsyarandomizeddoubleblindshamcontrolledclinicaltrial AT heidarimorteza clinicalandimagingoutcomesafterintrathecalinjectionofumbilicalcordtissuemesenchymalstemcellsincerebralpalsyarandomizeddoubleblindshamcontrolledclinicaltrial AT mohebihossein clinicalandimagingoutcomesafterintrathecalinjectionofumbilicalcordtissuemesenchymalstemcellsincerebralpalsyarandomizeddoubleblindshamcontrolledclinicaltrial AT fatemiali clinicalandimagingoutcomesafterintrathecalinjectionofumbilicalcordtissuemesenchymalstemcellsincerebralpalsyarandomizeddoubleblindshamcontrolledclinicaltrial AT garakaniamir clinicalandimagingoutcomesafterintrathecalinjectionofumbilicalcordtissuemesenchymalstemcellsincerebralpalsyarandomizeddoubleblindshamcontrolledclinicaltrial AT ashrafimahmoudreza clinicalandimagingoutcomesafterintrathecalinjectionofumbilicalcordtissuemesenchymalstemcellsincerebralpalsyarandomizeddoubleblindshamcontrolledclinicaltrial |